Literature DB >> 7695275

Selection and characterization of 5-fluoroorotate-resistant Plasmodium falciparum.

P K Rathod1, M Khosla, S Gassis, R D Young, C Lutz.   

Abstract

Previous studies have shown that 100 nM 5-fluoroorotate (5-FO) is sufficient to block the in vitro proliferation of Plasmodium falciparum without causing toxicity to mammalian cells. In anticipation of potential drug resistance, a study was undertaken to identify P. falciparum cells that would proliferate in the presence of 5-FO. About 3 x 10(6) UV-irradiated as well as nonirradiated parasites were subjected to a one-step selection with 100 nM 5-FO both in the absence and in the presence of preformed pyrimidines (uracil, uridine, thymine, and thymidine). The P. falciparum cells that emerged after 3 weeks were cloned, and the 90% inhibitory concentration of 5-FO for the cloned cells was found to be 100- to 400-fold greater than that for the parent cell line. Two clones that were further characterized retained resistance to 5-FO even after prolonged propagation in culture without drug pressure. Since the mutants were not cross-resistant to 5-fluorouracil or to dihydrofolate reductase inhibitors, it was unlikely that alteration of thymidylate synthase or overproduction of the bifunctional dihydrofolate reductase-thymidylate synthase was responsible for 5-FO resistance. Similarly, resistance was not due to the expression of a pyrimidine salvage pathway since the cells were not pyrimidine auxotrophs, they did not show increased utilization of pyrimidine nucleosides, and they did not show increased susceptibility to 5-fluoropyrimidine nucleosides. When the selection experiments were repeated, without mutagenesis, in the presence of 10(-7) M 5-FO with fewer than 10(6) parasites or in the presence of more than 10(-7) M 5-FO with more than 10(8) parasites, viable mutants could not be recovered from the cultures. The implications of these findings for the in vivo use of 5-FO for malaria chemotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695275      PMCID: PMC188299          DOI: 10.1128/AAC.38.12.2871

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Methotrexate-resistant Leishmania donovani genetically deficient in the folate-methotrexate transporter.

Authors:  K Kaur; T Coons; K Emmett; B Ullman
Journal:  J Biol Chem       Date:  1988-05-25       Impact factor: 5.157

2.  DNA amplification in arsenite-resistant Leishmania.

Authors:  S Detke; K Katakura; K P Chang
Journal:  Exp Cell Res       Date:  1989-01       Impact factor: 3.905

3.  Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro.

Authors:  P K Rathod; A Khatri; T Hubbert; W K Milhous
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria.

Authors:  D S Peterson; D Walliker; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum.

Authors:  J W Zolg; J R Plitt; G X Chen; S Palmer
Journal:  Mol Biochem Parasitol       Date:  1989-10       Impact factor: 1.759

6.  Purification of the bifunctional thymidylate synthase-dihydrofolate reductase complex from the human malaria parasite Plasmodium falciparum.

Authors:  G X Chen; J W Zolg
Journal:  Mol Pharmacol       Date:  1987-12       Impact factor: 4.436

7.  Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum.

Authors:  A F Cowman; M J Morry; B A Biggs; G A Cross; S J Foote
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine.

Authors:  M A Phillips; C C Wang
Journal:  Mol Biochem Parasitol       Date:  1987-01-02       Impact factor: 1.759

9.  Reductions in methotrexate and folate influx in methotrexate-resistant lines of Leishmania major are independent of R or H region amplification.

Authors:  T E Ellenberger; S M Beverley
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

10.  Plasmodium falciparum: cloning by single-erythrocyte micromanipulation and heterogeneity in vitro.

Authors:  A M Oduola; N F Weatherly; J H Bowdre; R E Desjardins
Journal:  Exp Parasitol       Date:  1988-06       Impact factor: 2.011

View more
  14 in total

Review 1.  How can we identify parasite genes that underlie antimalarial drug resistance?

Authors:  Tim Anderson; Standwell Nkhoma; Andrea Ecker; David Fidock
Journal:  Pharmacogenomics       Date:  2011-01       Impact factor: 2.533

2.  Variations in frequencies of drug resistance in Plasmodium falciparum.

Authors:  P K Rathod; T McErlean; P C Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

3.  Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase.

Authors:  Richard T Eastman; John White; Oliver Hucke; Kohei Yokoyama; Christophe L M J Verlinde; Michael A Hast; Lorena S Beese; Michael H Gelb; Pradipsinh K Rathod; Wesley C Van Voorhis
Journal:  Mol Biochem Parasitol       Date:  2006-12-22       Impact factor: 1.759

4.  Plasmodium Niemann-Pick type C1-related protein is a druggable target required for parasite membrane homeostasis.

Authors:  Eva S Istvan; Sudipta Das; Suyash Bhatnagar; Josh R Beck; Edward Owen; Manuel Llinas; Suresh M Ganesan; Jacquin C Niles; Elizabeth Winzeler; Akhil B Vaidya; Daniel E Goldberg
Journal:  Elife       Date:  2019-03-19       Impact factor: 8.140

Review 5.  Malaria evolution in South Asia: knowledge for control and elimination.

Authors:  Krishnamoorthy Narayanasamy; Laura Chery; Analabha Basu; Manoj T Duraisingh; Ananias Escalante; Joseph Fowble; Jennifer L Guler; Thurston Herricks; Ashwani Kumar; Partha Majumder; Jennifer Maki; Anjali Mascarenhas; Janneth Rodrigues; Bikram Roy; Somdutta Sen; Jayanthi Shastri; Joseph Smith; Neena Valecha; John White; Pradipsinh K Rathod
Journal:  Acta Trop       Date:  2012-01-14       Impact factor: 3.112

6.  Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.

Authors:  Richard T Eastman; Neekesh V Dharia; Elizabeth A Winzeler; David A Fidock
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 7.  Purine and pyrimidine pathways as targets in Plasmodium falciparum.

Authors:  María Belén Cassera; Yong Zhang; Keith Z Hazleton; Vern L Schramm
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

8.  Esterase mutation is a mechanism of resistance to antimalarial compounds.

Authors:  Eva S Istvan; Jeremy P Mallari; Victoria C Corey; Neekesh V Dharia; Garland R Marshall; Elizabeth A Winzeler; Daniel E Goldberg
Journal:  Nat Commun       Date:  2017-01-20       Impact factor: 14.919

9.  Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.

Authors:  L Jiang; P C Lee; J White; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance.

Authors:  S Gassis; P K Rathod
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.